Picture of Briacell Therapeutics logo

BCTX Briacell Therapeutics Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Annual income statement for Briacell Therapeutics, fiscal year end - July 31st, USD millions except per share, conversion factor applied.

2019
July 31st
2020
July 31st
R2021
July 31st
2022
July 31st
2023
July 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
USG
USG
USG
Status:
fx
Final
fx
Final
FinalFinalFinal
Total Revenue00000
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses4.73.587.1115.323.3
Operating Profit-4.7-3.58-7.11-15.3-23.3
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-4.37-3.67-13.8-26.8-20.3
Net Income After Taxes-4.37-3.67-13.8-26.8-20.3
Net Income Before Extraordinary Items
Net Income-4.37-3.67-13.8-26.8-20.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-4.37-3.67-13.8-26.8-20.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-7.55-5.18-3.03-1.73-1.3